Taken together, these data demonstrate that the c-MYC-mRNA drug achieved dose-dependent, on-target inhibition of the lethal pancreatic tumors via dose-dependent downregulation of the c-MYC and PD-L1 expression. This evidence concerns the gene MYC and pancreatic neoplasm.